Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Blood Cancer Drugs Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 Blood Chemotherapy Drugs
1.2.3 Blood Targeted Therapy Drugs
1.3 Market by Application
1.3.1 Global Blood Cancer Drugs Market Growth by Application: 2018 VS 2024 VS 2034
1.3.2 Leukemia
1.3.3 lymphoma
1.3.4 Multiple Myeloma
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Blood Cancer Drugs Market Perspective (2018-2034)
2.2 Blood Cancer Drugs Growth Trends by Region
2.2.1 Global Blood Cancer Drugs Market Size by Region: 2018 VS 2024 VS 2034
2.2.2 Blood Cancer Drugs Historic Market Size by Region (2018-2023)
2.2.3 Blood Cancer Drugs Forecasted Market Size by Region (2024-2034)
2.3 Blood Cancer Drugs Market Dynamics
2.3.1 Blood Cancer Drugs Industry Trends
2.3.2 Blood Cancer Drugs Market Drivers
2.3.3 Blood Cancer Drugs Market Challenges
2.3.4 Blood Cancer Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Blood Cancer Drugs Players by Revenue
3.1.1 Global Top Blood Cancer Drugs Players by Revenue (2018-2023)
3.1.2 Global Blood Cancer Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Blood Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Blood Cancer Drugs Revenue
3.4 Global Blood Cancer Drugs Market Concentration Ratio
3.4.1 Global Blood Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Blood Cancer Drugs Revenue in 2024
3.5 Blood Cancer Drugs Key Players Head office and Area Served
3.6 Key Players Blood Cancer Drugs Product Solution and Service
3.7 Date of Enter into Blood Cancer Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Blood Cancer Drugs Breakdown Data by Type
4.1 Global Blood Cancer Drugs Historic Market Size by Type (2018-2023)
4.2 Global Blood Cancer Drugs Forecasted Market Size by Type (2024-2034)
5 Blood Cancer Drugs Breakdown Data by Application
5.1 Global Blood Cancer Drugs Historic Market Size by Application (2018-2023)
5.2 Global Blood Cancer Drugs Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Blood Cancer Drugs Market Size (2018-2034)
6.2 North America Blood Cancer Drugs Market Growth Rate by Country: 2018 VS 2024 VS 2034
6.3 North America Blood Cancer Drugs Market Size by Country (2018-2023)
6.4 North America Blood Cancer Drugs Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Blood Cancer Drugs Market Size (2018-2034)
7.2 Europe Blood Cancer Drugs Market Growth Rate by Country: 2018 VS 2024 VS 2034
7.3 Europe Blood Cancer Drugs Market Size by Country (2018-2023)
7.4 Europe Blood Cancer Drugs Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Blood Cancer Drugs Market Size (2018-2034)
8.2 Asia-Pacific Blood Cancer Drugs Market Growth Rate by Region: 2018 VS 2024 VS 2034
8.3 Asia-Pacific Blood Cancer Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Blood Cancer Drugs Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Blood Cancer Drugs Market Size (2018-2034)
9.2 Latin America Blood Cancer Drugs Market Growth Rate by Country: 2018 VS 2024 VS 2034
9.3 Latin America Blood Cancer Drugs Market Size by Country (2018-2023)
9.4 Latin America Blood Cancer Drugs Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Blood Cancer Drugs Market Size (2018-2034)
10.2 Middle East & Africa Blood Cancer Drugs Market Growth Rate by Country: 2018 VS 2024 VS 2034
10.3 Middle East & Africa Blood Cancer Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Blood Cancer Drugs Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen,
11.1.1 Amgen, Company Detail
11.1.2 Amgen, Business Overview
11.1.3 Amgen, Blood Cancer Drugs Introduction
11.1.4 Amgen, Revenue in Blood Cancer Drugs Business (2018-2023)
11.1.5 Amgen, Recent Development
11.2 AstraZeneca PLC,
11.2.1 AstraZeneca PLC, Company Detail
11.2.2 AstraZeneca PLC, Business Overview
11.2.3 AstraZeneca PLC, Blood Cancer Drugs Introduction
11.2.4 AstraZeneca PLC, Revenue in Blood Cancer Drugs Business (2018-2023)
11.2.5 AstraZeneca PLC, Recent Development
11.3 Astellas Pharma,
11.3.1 Astellas Pharma, Company Detail
11.3.2 Astellas Pharma, Business Overview
11.3.3 Astellas Pharma, Blood Cancer Drugs Introduction
11.3.4 Astellas Pharma, Revenue in Blood Cancer Drugs Business (2018-2023)
11.3.5 Astellas Pharma, Recent Development
11.4 Bayer AG,
11.4.1 Bayer AG, Company Detail
11.4.2 Bayer AG, Business Overview
11.4.3 Bayer AG, Blood Cancer Drugs Introduction
11.4.4 Bayer AG, Revenue in Blood Cancer Drugs Business (2018-2023)
11.4.5 Bayer AG, Recent Development
11.5 Bristol-Myers Squibb Company,
11.5.1 Bristol-Myers Squibb Company, Company Detail
11.5.2 Bristol-Myers Squibb Company, Business Overview
11.5.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Introduction
11.5.4 Bristol-Myers Squibb Company, Revenue in Blood Cancer Drugs Business (2018-2023)
11.5.5 Bristol-Myers Squibb Company, Recent Development
11.6 Celgene Corporation,
11.6.1 Celgene Corporation, Company Detail
11.6.2 Celgene Corporation, Business Overview
11.6.3 Celgene Corporation, Blood Cancer Drugs Introduction
11.6.4 Celgene Corporation, Revenue in Blood Cancer Drugs Business (2018-2023)
11.6.5 Celgene Corporation, Recent Development
11.7 Eli Lilly,
11.7.1 Eli Lilly, Company Detail
11.7.2 Eli Lilly, Business Overview
11.7.3 Eli Lilly, Blood Cancer Drugs Introduction
11.7.4 Eli Lilly, Revenue in Blood Cancer Drugs Business (2018-2023)
11.7.5 Eli Lilly, Recent Development
11.8 F.Hoffmann-La Roche,
11.8.1 F.Hoffmann-La Roche, Company Detail
11.8.2 F.Hoffmann-La Roche, Business Overview
11.8.3 F.Hoffmann-La Roche, Blood Cancer Drugs Introduction
11.8.4 F.Hoffmann-La Roche, Revenue in Blood Cancer Drugs Business (2018-2023)
11.8.5 F.Hoffmann-La Roche, Recent Development
11.9 Johnson & Johnson,
11.9.1 Johnson & Johnson, Company Detail
11.9.2 Johnson & Johnson, Business Overview
11.9.3 Johnson & Johnson, Blood Cancer Drugs Introduction
11.9.4 Johnson & Johnson, Revenue in Blood Cancer Drugs Business (2018-2023)
11.9.5 Johnson & Johnson, Recent Development
11.10 Novartis
11.10.1 Novartis Company Detail
11.10.2 Novartis Business Overview
11.10.3 Novartis Blood Cancer Drugs Introduction
11.10.4 Novartis Revenue in Blood Cancer Drugs Business (2018-2023)
11.10.5 Novartis Recent Development
11.11 Pfizer,
11.11.1 Pfizer, Company Detail
11.11.2 Pfizer, Business Overview
11.11.3 Pfizer, Blood Cancer Drugs Introduction
11.11.4 Pfizer, Revenue in Blood Cancer Drugs Business (2018-2023)
11.11.5 Pfizer, Recent Development
11.12 Takeda Pharmaceutical Company Ltd,
11.12.1 Takeda Pharmaceutical Company Ltd, Company Detail
11.12.2 Takeda Pharmaceutical Company Ltd, Business Overview
11.12.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Introduction
11.12.4 Takeda Pharmaceutical Company Ltd, Revenue in Blood Cancer Drugs Business (2018-2023)
11.12.5 Takeda Pharmaceutical Company Ltd, Recent Development
11.13 AbbVie
11.13.1 AbbVie Company Detail
11.13.2 AbbVie Business Overview
11.13.3 AbbVie Blood Cancer Drugs Introduction
11.13.4 AbbVie Revenue in Blood Cancer Drugs Business (2018-2023)
11.13.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Blood Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2024 VS 2034
Table 2. Key Players of Blood Chemotherapy Drugs
Table 3. Key Players of Blood Targeted Therapy Drugs
Table 4. Global Blood Cancer Drugs Market Size Growth by Application (US$ Million): 2018 VS 2024 VS 2034
Table 5. Global Blood Cancer Drugs Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 6. Global Blood Cancer Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Blood Cancer Drugs Market Share by Region (2018-2023)
Table 8. Global Blood Cancer Drugs Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 9. Global Blood Cancer Drugs Market Share by Region (2024-2034)
Table 10. Blood Cancer Drugs Market Trends
Table 11. Blood Cancer Drugs Market Drivers
Table 12. Blood Cancer Drugs Market Challenges
Table 13. Blood Cancer Drugs Market Restraints
Table 14. Global Blood Cancer Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Blood Cancer Drugs Market Share by Players (2018-2023)
Table 16. Global Top Blood Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Drugs as of 2024)
Table 17. Ranking of Global Top Blood Cancer Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Blood Cancer Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Blood Cancer Drugs Product Solution and Service
Table 21. Date of Enter into Blood Cancer Drugs Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Blood Cancer Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Blood Cancer Drugs Revenue Market Share by Type (2018-2023)
Table 25. Global Blood Cancer Drugs Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 26. Global Blood Cancer Drugs Revenue Market Share by Type (2024-2034)
Table 27. Global Blood Cancer Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Blood Cancer Drugs Revenue Market Share by Application (2018-2023)
Table 29. Global Blood Cancer Drugs Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 30. Global Blood Cancer Drugs Revenue Market Share by Application (2024-2034)
Table 31. North America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 32. North America Blood Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Blood Cancer Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 34. Europe Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 35. Europe Blood Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Blood Cancer Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 37. Asia-Pacific Blood Cancer Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2024 VS 2034
Table 38. Asia-Pacific Blood Cancer Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Blood Cancer Drugs Market Size by Region (2024-2034) & (US$ Million)
Table 40. Latin America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 41. Latin America Blood Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Blood Cancer Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 43. Middle East & Africa Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 44. Middle East & Africa Blood Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Blood Cancer Drugs Market Size by Country (2024-2034) & (US$ Million)
Table 46. Amgen, Company Detail
Table 47. Amgen, Business Overview
Table 48. Amgen, Blood Cancer Drugs Product
Table 49. Amgen, Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 50. Amgen, Recent Development
Table 51. AstraZeneca PLC, Company Detail
Table 52. AstraZeneca PLC, Business Overview
Table 53. AstraZeneca PLC, Blood Cancer Drugs Product
Table 54. AstraZeneca PLC, Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 55. AstraZeneca PLC, Recent Development
Table 56. Astellas Pharma, Company Detail
Table 57. Astellas Pharma, Business Overview
Table 58. Astellas Pharma, Blood Cancer Drugs Product
Table 59. Astellas Pharma, Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 60. Astellas Pharma, Recent Development
Table 61. Bayer AG, Company Detail
Table 62. Bayer AG, Business Overview
Table 63. Bayer AG, Blood Cancer Drugs Product
Table 64. Bayer AG, Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 65. Bayer AG, Recent Development
Table 66. Bristol-Myers Squibb Company, Company Detail
Table 67. Bristol-Myers Squibb Company, Business Overview
Table 68. Bristol-Myers Squibb Company, Blood Cancer Drugs Product
Table 69. Bristol-Myers Squibb Company, Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 70. Bristol-Myers Squibb Company, Recent Development
Table 71. Celgene Corporation, Company Detail
Table 72. Celgene Corporation, Business Overview
Table 73. Celgene Corporation, Blood Cancer Drugs Product
Table 74. Celgene Corporation, Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 75. Celgene Corporation, Recent Development
Table 76. Eli Lilly, Company Detail
Table 77. Eli Lilly, Business Overview
Table 78. Eli Lilly, Blood Cancer Drugs Product
Table 79. Eli Lilly, Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 80. Eli Lilly, Recent Development
Table 81. F.Hoffmann-La Roche, Company Detail
Table 82. F.Hoffmann-La Roche, Business Overview
Table 83. F.Hoffmann-La Roche, Blood Cancer Drugs Product
Table 84. F.Hoffmann-La Roche, Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 85. F.Hoffmann-La Roche, Recent Development
Table 86. Johnson & Johnson, Company Detail
Table 87. Johnson & Johnson, Business Overview
Table 88. Johnson & Johnson, Blood Cancer Drugs Product
Table 89. Johnson & Johnson, Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 90. Johnson & Johnson, Recent Development
Table 91. Novartis Company Detail
Table 92. Novartis Business Overview
Table 93. Novartis Blood Cancer Drugs Product
Table 94. Novartis Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 95. Novartis Recent Development
Table 96. Pfizer, Company Detail
Table 97. Pfizer, Business Overview
Table 98. Pfizer, Blood Cancer Drugs Product
Table 99. Pfizer, Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 100. Pfizer, Recent Development
Table 101. Takeda Pharmaceutical Company Ltd, Company Detail
Table 102. Takeda Pharmaceutical Company Ltd, Business Overview
Table 103. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product
Table 104. Takeda Pharmaceutical Company Ltd, Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 105. Takeda Pharmaceutical Company Ltd, Recent Development
Table 106. AbbVie Company Detail
Table 107. AbbVie Business Overview
Table 108. AbbVie Blood Cancer Drugs Product
Table 109. AbbVie Revenue in Blood Cancer Drugs Business (2018-2023) & (US$ Million)
Table 110. AbbVie Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Blood Cancer Drugs Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Blood Cancer Drugs Market Share by Type: 2024 VS 2034
Figure 3. Blood Chemotherapy Drugs Features
Figure 4. Blood Targeted Therapy Drugs Features
Figure 5. Global Blood Cancer Drugs Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 6. Global Blood Cancer Drugs Market Share by Application: 2024 VS 2034
Figure 7. Leukemia Case Studies
Figure 8. lymphoma Case Studies
Figure 9. Multiple Myeloma Case Studies
Figure 10. Blood Cancer Drugs Report Years Considered
Figure 11. Global Blood Cancer Drugs Market Size (US$ Million), Year-over-Year: 2018-2034
Figure 12. Global Blood Cancer Drugs Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Blood Cancer Drugs Market Share by Region: 2024 VS 2034
Figure 14. Global Blood Cancer Drugs Market Share by Players in 2024
Figure 15. Global Top Blood Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Drugs as of 2024)
Figure 16. The Top 10 and 5 Players Market Share by Blood Cancer Drugs Revenue in 2024
Figure 17. North America Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 18. North America Blood Cancer Drugs Market Share by Country (2018-2034)
Figure 19. United States Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 20. Canada Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 21. Europe Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 22. Europe Blood Cancer Drugs Market Share by Country (2018-2034)
Figure 23. Germany Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 24. France Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 25. U.K. Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 26. Italy Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 27. Russia Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 28. Nordic Countries Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 29. Asia-Pacific Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 30. Asia-Pacific Blood Cancer Drugs Market Share by Region (2018-2034)
Figure 31. China Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 32. Japan Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 33. South Korea Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 34. Southeast Asia Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 35. India Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 36. Australia Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 37. Latin America Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 38. Latin America Blood Cancer Drugs Market Share by Country (2018-2034)
Figure 39. Mexico Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 40. Brazil Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 41. Middle East & Africa Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 42. Middle East & Africa Blood Cancer Drugs Market Share by Country (2018-2034)
Figure 43. Turkey Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 44. Saudi Arabia Blood Cancer Drugs Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 45. Amgen, Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 46. AstraZeneca PLC, Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 47. Astellas Pharma, Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 48. Bayer AG, Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 49. Bristol-Myers Squibb Company, Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 50. Celgene Corporation, Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 51. Eli Lilly, Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 52. F.Hoffmann-La Roche, Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 53. Johnson & Johnson, Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 54. Novartis Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 55. Pfizer, Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 56. Takeda Pharmaceutical Company Ltd, Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 57. AbbVie Revenue Growth Rate in Blood Cancer Drugs Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed